Should You Do PGT-A With Donor Eggs?

Egg Donors

PGT-A can be used with donor eggs, but it is not automatically needed. Learn what it tests, why routine use is not recommended for every donor-egg cycle, and what to ask your fertility clinic.

Short answer: PGT-A can be performed on embryos created with donor eggs, but using donor eggs does not automatically mean the test is needed. Because egg donors are usually young and carefully screened, embryos made from donor eggs may already have a lower risk of age-related chromosome errors than embryos made with eggs from an older patient. The decision should be individualized with your fertility specialist and, when appropriate, a genetic counselor.

What does PGT-A test?

Preimplantation genetic testing for aneuploidy, or PGT-A, estimates whether an embryo has the expected number of chromosomes. It is performed after IVF, usually by removing a small sample of cells from a blastocyst and testing those cells in a genetics laboratory. The embryo is generally frozen while results are pending.

PGT-A is different from donor carrier screening. Carrier screening looks for inherited gene variants in the egg donor and the person providing sperm. PGT-A evaluates chromosome copy number in an embryo. It also differs from PGT-M, which is designed to test embryos for a specific single-gene condition, and PGT-SR, which is used when a genetic parent has certain structural chromosome rearrangements.

Can embryos made with donor eggs be tested?

Yes. Once donor eggs are fertilized and develop into blastocysts, the embryos can generally undergo the same biopsy and PGT-A process used for embryos created with a patient's own eggs. Whether testing is technically appropriate depends on the number and development of the embryos, the laboratory's protocols, and the intended parents' clinical circumstances.

Testing is not performed on the egg itself. It is performed on cells taken from an embryo after fertilization and several days of development.

Why might intended parents consider PGT-A?

Some intended parents consider PGT-A because it may provide additional information for choosing which embryo to transfer first. A clinic may discuss it when:

several blastocysts are available and the team wants another tool for embryo prioritization;
the sperm provider's reproductive or chromosome history raises a separate concern;
there have been previous implantation failures or pregnancy losses, although the usefulness of PGT-A depends on the cause and evidence for the specific situation;
a gestational carrier will receive the embryo and the intended parents wish to discuss every reasonable strategy for reducing avoidable transfers; or
PGT-M or PGT-SR is already planned and the genetics team is considering whether PGT-A should be added.

These are reasons to have a clinical discussion, not automatic indications that testing will improve the chance of a baby.

Why is PGT-A not routine with donor eggs?

The American Society for Reproductive Medicine's 2024 committee opinion concluded that available evidence is insufficient to recommend routine PGT-A in donor-oocyte cycles. Donor eggs typically come from younger people, so the expected rate of age-related embryo aneuploidy is lower than it is when eggs come from an older patient. Current studies have not established that routine testing of donor-egg embryos improves the cumulative chance of live birth for every recipient.

PGT-A also has tradeoffs. It adds cost, usually requires embryo biopsy and freezing, may extend the treatment timeline, and can produce mosaic or inconclusive results that require careful interpretation. A result is a screening result, not a guarantee that an embryo will or will not produce a healthy pregnancy.

Does the recipient's age change the answer?

The age most directly related to age-associated chromosome errors in the embryo is the age of the person whose egg was used. Therefore, the egg donor's age is generally more relevant to embryo aneuploidy risk than the recipient's age. The recipient's health and age can still matter for pregnancy safety, uterine preparation and obstetric care, but those issues are evaluated separately from PGT-A.

What if a gestational surrogate will carry the pregnancy?

Using a gestational surrogate does not by itself make PGT-A mandatory. The embryo's chromosomes come from the egg and sperm sources, not from the person carrying the pregnancy. Clinics may still discuss testing because an unsuccessful transfer affects the surrogate as well as the intended parents, but the potential benefit must be weighed against the number of available embryos, the egg donor's age, cost and the limits of the test.

For more context, read Is PGT-A Required for Surrogacy? and What Does Embryo Grading Mean, and Can a Low-Grade Embryo Succeed?

Questions to ask your fertility clinic

What specific benefit do you expect PGT-A to provide in our donor-egg cycle?
How many blastocysts do you expect to be available for biopsy?
What are your laboratory's rates of inconclusive and mosaic results?
How would each possible result change the order or eligibility of embryos for transfer?
What are the biopsy, testing, freezing and storage costs?
Would you recommend genetic counseling before we decide?
What prenatal screening or diagnostic testing would still be offered after pregnancy begins?

Donor screening and embryo testing answer different questions

Even when PGT-A is used, intended parents should still review the donor's medical and family history and carrier-screening results alongside the sperm provider's results. See What Genetic Screening Should You Review Before Choosing an Egg Donor? Donor screening, embryo screening and prenatal testing are complementary; none replaces all the others.

Bottom line

You can use PGT-A with donor eggs, but it is not automatically beneficial or routinely recommended for every donor-egg IVF cycle. Ask your fertility clinic to explain the expected benefit for your specific embryos, the limitations of the test, the possible outcomes and the total cost before deciding.

If you are comparing egg donors, fertility providers or surrogacy options, Expecting.ai can help you explore profiles and connect with relevant providers.

This article is for general educational purposes and is not medical or genetic advice. Treatment decisions should be made with a qualified fertility specialist and, when appropriate, a genetic counselor.